Drug deprescribing policy and incentives in France

Francis Megerlin (), Gilles Bouvenot and Patrice Queneau
Additional contact information
Francis Megerlin: CEIE - Centre d'études internationales et européennes - UNISTRA - Université de Strasbourg, Académie nationale de Pharmacie
Gilles Bouvenot: INSERM - Institut National de la Santé et de la Recherche Médicale, Académie nationale de médecine
Patrice Queneau: Service de Médecine interne [CHU Saint-Etienne] - CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] - UJM - Université Jean Monnet - Saint-Étienne, Académie nationale de médecine

Post-Print from HAL

Abstract: Deprescribing inappropriate drug treatments is a public health issue particularly in countries with a high level of polymedication (polypharmacy). Despite the introduction of the term ‘deprescribing' in France in 2002 and the clinical practice guidelines, progress in the outpatient sector has been limited. Our article describes the financial incentives adopted by national agreements between the Assurance Maladie (France's compulsory health insurer scheme) and unions of independent practitioners: pharmacists are encouraged to draw up and share medication reviews (since 2018, target population extended in 2022). As the outcomes have been modest, doctors have then been since 2024 also incentivised to offer medical consultations explicitly dedicated to deprescribing, and to prescribe medication reviews to be drawn up by pharmacists. This article describes the new legal framework for outpatient and inpatient services. It calls for the results expected from 2025 onwards to be measured and studied in national health databases, thanks to the coding associated with these new services.

Keywords: Deprescribing; Polypharmacy; Financial incentives; Physicians; Pharmacists; France (search for similar items in EconPapers)
Date: 2025-04
References: Add references at CitEc
Citations:

Published in Annales Pharmaceutiques Françaises, 2025, ⟨10.1016/j.pharma.2025.04.003⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-05086560

DOI: 10.1016/j.pharma.2025.04.003

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().